The pattern of neurodegeneration in Huntington's disease: A comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease

Neuroscience

Volumn 97, Issue 3, 2000, Pages 505-519

  Glass, M ^a   Dragunow, M ^a   Faull, R L M ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Caudate nucleus; Globus pallidus; Putamen; Receptor changes; Substantia nigra

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ADENOSINE A2A RECEPTOR; CANNABINOID RECEPTOR; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR;

ARTICLE; AUTORADIOGRAPHY; BASAL GANGLION; CAUDATE NUCLEUS; CONTROLLED STUDY; GLOBUS PALLIDUS; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; NERVE DEGENERATION; NEUROPATHOLOGY; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

AGED; AGED, 80 AND OVER; BASAL GANGLIA; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; NERVE DEGENERATION; RECEPTOR, ADENOSINE A2A; RECEPTORS, CANNABINOID; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RECEPTORS, DRUG; RECEPTORS, GABA-A; RECEPTORS, PURINERGIC P1;

EID: 0034081681     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(00)00008-7     Document Type: Article

References (68)

1. Albin R.L., Reiner A., Anderson K.D., Dure L.S., Handelin B., Balfour R., Whetsell W.O.J., Penney J.B., Young A.B. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease. Ann. Neurol. 31:1992;425-430.
2. Albin R.L., Young A.B., Penney J.B. The functional anatomy of basal ganglia disorders. Trends Neurosci. 12:1989;366-375.
3. Aubry J.M., Schulz M.F., Pagliusi S., Schulz P., Kiss J.Z. Co-expression of dopamine D2 and substance P (neurokinin-1) receptor messenger RNAs by a sub-population of cholinergic neurons in the rat caudate nucleus and putamen. Neuroscience. 53:1993;417-424.
4. Augood S.J., Faull R.L.M., Emson P.C. Dopamine D1 and D2 receptor gene expression in Huntington's disease caudate nucleus and putamen. Ann. Neurol. 42:1997;215-221.
5. Augood S.J., Faull R.L.M., Love D.R., Emson P.C. Reduction in enkephalin and substance P messenger RNA in the caudate nucleus and putamen of early grade Huntington's disease: a detailed cellular in situ hybridization study. Neuroscience. 72:1996;1023-1036.
6. Beckstead R.M., Cruz C.J. Striatal axons to the globus pallidus entopenduncular nucleus and substantia nigra come mainly from separate cell populations in cat. Neuroscience. 19:1986;147-158.
7. Camps M., Cortes R., Gueye B., Probst A., Palacios J.M. Dopamine-receptors in human brain - autoradiographic distribution of D2 sites. Neuroscience. 28:1989;275-290.
8. Chan G.C.K., Hinds T.R., Impey S., Storm D.R. Hippocampal neurotoxicity of delta(9)-tetrahydrocannabinol. J. Neurosci. 18:1998;5322-5332.
9. Cortes R., Gueye B., Pazos A., Probst A., Palacios J.M. Dopamine-receptors in human brain - autoradiographic distribution of D1 sites. Neuroscience. 28:1989;263-273.
10. Dawbarn D., De Quidt M.E., Emson P.C. Survival of basal ganglia neuropeptide-Y somatostatin neurons in Huntington's disease. Brain Res. 340:1985;251-260.
11. Dragunow M., Tse C., Glass M., Lawlor P.A. C-fos antisense inhibits basal expression of Krox 24 in rat caudate and neocortex. Cell. molec. Neurobiol. 14:1994;395-405.
12. Enna S.J., Bennett J.P., Bylund D.B., Snyder S.H., Bird E.D., Iversen L.L. Alterations of brain neurotransmitter binding in Huntington's chorea. Brain Res. 16:1976;531-537.
13. Eshhar N., Striem S., Biegon A. HU-211, a non-psychotropic cannabinoid, rescues cortical-neurons from excitatory amino-acid toxicity in culture. NeuroReport. 5:1993;237-240.
14. Faull R.L.M., Villiger J.W. Benzodiazepine receptors in the human spinal cord: a detailed anatomical and pharmacological study. Neuroscience. 17:1986;791-802.
15. Faull R.L.M., Villiger J.W. Multiple benzodiazepine receptors in the human basal ganglia: a detailed pharmacological and anatomical study. Neuroscience. 24:1988;433-451.
16. Faull R.L.M., Waldvogel H.J., Nicholson L.F.B., Synek B.J.L. The distribution of GABAa-benzodiazepine receptors in the basal ganglia in Huntington's disease and in the quinolinic acid lesioned rat. Prog. Brain Res. 99:1993;105-123.
17. A receptor changes in the basal ganglia in Huntington's disease in the human brain and in the quinolinic acid lesioned rat model of the disease following fetal neuron transplants. In Neurotransmitters in the Human Brain. (eds Tracey D., Stone J. and Paxinos G.), pp. 173-198. Plenum, New York.
18. Ferrante R.J., Beal M.F., Kowall K.W., Richardson E.P., Martin J.B. Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease. Brain Res. 411:1987;162-166.
19. Ferrante R.J., Kowall N.W., Beal M.F., Richardson E.D., Bird E.D., Martin J.B. Selective sparing of a class of striatal neurons in Huntington's disease. Science. 230:1985;561-564.
20. Ferre S., von Euler G., Johansoon B., Fredholm B.B., Fuxe K. Stimulation of high affinity adenosine A2 receptors decrease the affinity of dopamine D2 receptors in rat striatal membranes. Proc. natn. Acad. Sci. U.S.A. 88:1991;7238-7241.
21. Fink J.S., Weaver D.R., Rivkees S.A., Peterfreund R.A., Pollack A.E., Alder E.M., Reppert S.M. Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat caudate nucleus and putamen. Molec. Brain Res. 14:1992;186-195.
22. Gimenez-Amaya J.M., Graybiel A.M. Compartmental origins of the striatopallidal projection in the primate. Neuroscience. 34:1990;111-126.
23. Giuffrida A., Parsons L.H., Kerr T.M., Rodríguez De Fonseca F., Navarro M., Piomelli D. Dopamine activaton of endogenous cannabinoid signaling in dorsal caudate nucleus and putamen. Nature Neurosci. 2:1999;358-363.
24. Glass M., Dragunow M., Faull R.L.M. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience. 77:1997;299-318.
25. Glass M., Faull R.L.M., Dragunow M. Loss of cannabinoid receptors in the substantia nigra in Huntington's disease. Neuroscience. 56:1993;523-527.
26. Glass M., Faull R.L.M., Dragunow M. Localisation of the adenosine uptake site in the human brain: a comparison with the distribution of adenosine A1 receptors. Brain Res. 710:1996;79-91.
27. Graveland G.A., Williams R.S., Difiglia M. Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's desease. Science. 227:1985;770-773.
28. Graybiel A.M. Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci. 13:1990;244-254.
29. Hedreen J.C., Folstein S.E. Early loss of neostriatal striosome neurons in Huntington's disease. J. Neuropath. exp. Neurol. 54:1995;105-120.
30. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Cannabinoid receptor localization in brain. Proc. natn. Acad. Sci. U.S.A. 87:1990;1932-1936.
31. Hill M. P., Di Marzo V., Bisogno T., Ambrosino G., Crossman A. R. and Brotchie J. M. (1999) Endocannabinoids and the control of movement and generation of symptoms in Parkinson's disease. Proceedings of the Symposium on the Cannabinoids, Burlington, Vermont, International Cannabinoid Research Society, p. 70.
32. Hirsch E.C., Graybiel A.M., Hersh L.B. Striosomes and extrastiosomal matrix contain different amounts of immunoreactive choline acetyltransferase in the human caudate nucleus and putamen. Neurosci. Lett. 96:1989;145-150.
33. James S., Xuereb J.H., Askalan R., Richardson P.J. Adenosine receptors in post-mortem human brain. Br. J. Pharmac. 165:1992;238-244.
34. Le Moine C., Bloch B. D1 and D2 dopamine receptor gene expression in the rat caudate nucleus and putamen: sensitive cRNA probes demonstrate prominent segregation of D1 and D2 mRNAs in distinct neuronal populations of the dorsal and ventral caudate nucleus and putamen. J. comp. Neurol. 35:1995;418-426.
35. Le Moine C., Normand E., Bloch B. Phenotypical characterization of the rat striatal neurons expressing the D1 dopamine receptor gene. Proc. natn. Acad. Sci. U.S.A. 88:1991;4205-4209.
36. Leweke F.M., Gluffrida A., Wurster U., Emrich H.M., Piomelli D. Elevated endogenous cannabinoids in schizophrenia. NeuroReport. 10:1999;1665-1669.
37. Mailleux P., Vanderhaeghen J.J. Localization of cannabinoid receptor in the human developing and adult basal ganglia. Higher levels in the striatonigral neurons. Neurosci. Lett. 148:1992;173-176.
38. Martinez-Mir M.I., Probst A., Palacios J.M. Adenosine A2 receptors: selective localization in the human basal ganglia and alterations with disease. Neuroscience. 42:1991;697-706.
39. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:1990;561-564.
40. Mayfield R.D., Suzuki F., Zahniser N.R. Adenosine A2a receptor modulation of electrically evoked endogenous GABA release from slices of rat globus pallidus. J. Neurochem. 60:1993;2334-2337.
41. Miller A.S., Walker J.M. Effects of a cannabinoid on spontaneous and evoked neuronal-activity in the substantia-nigra pars reticulata. Eur. J. Pharmac. 279:1995;179-185.
42. Morton A.J., Nicholson L.F.B., Faull R.L.M. Compartmental loss of NADPH diaphorase in the neuropil of the human caudate nucleus and putamen in Huntington's disease. Neuroscience. 53:1993;159-168.
43. Myers R.H., Vonsattel J.P., Paskevich P.A., Keily D.K., Stevens T.J., Cupples L.A., Richardson E.P., Bird E.D. Decreased neuronal and increased oligodendroglial densities in Huntington's disease caudate nucleus. J. Neuropath. exp. Neurol. 50:1991;729-742.
44. Nadler V., Biegon A., Beityannai E., Adamchik J., Shohami E. Ca-45 accumulation in rat-brain after closed-head injury - attenuation by the novel neuroprotective agent HU-211. Brain Res. 685:1995;1-11.
45. Oviedo A., Glowa J., Herkenham M. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study. Brain Res. 616:1993;293-302.
46. Parent A., Bouchard C., Smith Y. The striatopallidal and striatonigral projections: two distinct fibre systems in primate. Brain Res. 303:1984;385-390.
47. Penney J.B., Young A.B. Quantitative autoradiography of neurotransmitter receptors in Huntington's disease. Neurology. 32:1982;1391-1395.
48. Popoli P., Pèzzola A., Reggio R., Caporali M.G., Scotti de Capolis A. CGS 21680 antagonises motor hyperactivity in a rat model of Huntington's disease. Eur. J. Pharmac. 257:1994;R5-R6.
49. Reiner A., Albin R.L., Anderson K.D., D'Amato C.J., Penney J.B., Young A.B. Differential loss of striatal projection neurons in Huntington's disease. Proc. natn. Acad. Sci. U.S.A. 85:1988;5733-5737.
50. Reiner A., Anderson K.D. The patterns of neurotransmiter and neuropeptide co-occurance among striatal neurons. Conclusions based on recent findings. Brain Res. Rev. 15:1990;251-265.
51. Reisine T.D., Overstreet D., Gale K., Rossor M., Iversen L., Yamamura H.I. Benzodiazepine receptors: the effect of GABA on their characteristics in human brain and their alterations in Huntington's disease. Brain Res. 199:1980;79-88.
52. Reynolds G.P., Pearson S.J. Brain GABA levels in asymptomatic Huntington's disease. New Engl. J. Med. 287:1990;682.
53. Richfield E.K., Herkenham M. Selective vulnerability in Huntington's disease: preferential loss of cannabinoid receptors in lateral globus pallidus. Ann. Neurol. 36:1994;577-584.
54. Richfield E.K., O'Brien C.F., Eskin T., Shoulson I. Heterogenous dopamine receptor changes in early and late Huntington's disease. Neurosci. Lett. 132:1991;121-126.
55. Sañudo-Peña M.C., Patrick S.L., Patrick R.L., Walker J.M. Effects of intranigral cannabinoids on rotational behaviour in rats: interactions with the dopaminergic system. Neurosci. Lett. 206:1996;21-24.
56. Sañudo-Peña M.C., Walker J.M. Role of the subthalamic nucleus in cannabinoid actions in the substantia nigra of the rat. J. Neurophysiol. 77:1997;1635-1638.
57. Sañudo-Peña M.C., Walker J.M. Effects of intrapallidal cannabinoids on rotational behaviour in rats: interactions with dopaminergic systems. Synapse. 28:1998;27-32.
58. Sapp E., Ge P., Aizawa H., Bird E., Penney J., Young A.B., Vonsattel J.P., Difiglia M. Evidence for a preferential loss of enkephalin immunoreactivity in the external globus-pallidus in low-grade Huntingtons disease using high-resolution image-analysis. Neuroscience. 64:1995;397-404.
59. Schiffman S.N., Jacobs O., Vanderhaeghen J.J. Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not be substance P neurons: an in situ hybridization histochemistry study. J. Neurochem. 57:1991;1062-1067.
60. Schiffmann S.N., Vanderhaeghen J.J. Adenosine A2 receptors regulate the gene expression of striatopallidal and striatonigral neurons. J. Neurosci. 13:1993;1080-1087.
61. Spokes E.G. Neurochemical alterations in Huntington's chorea - a study of postmortem brain tissue. Brain. 103:1980;179-210.
62. Steiner H., Bonner T.I., Zimmer A.M., Kitai S.T., Zimmer A. Altered gene expression in striatal projection neurons in CB1 cannabinoid receptor knockout mice. Proc. natn. Acad. Sci. U.S.A. 96:1999;5786-5790.
63. Storey E., Beal M.F. Neurochemical substrates of rigidity and chorea in Huntingtons-disease. Brain. 116:1990;1201-1222.
64. Szabo B., Dörner L., Pfeundtner C., Nörenberg W., Starke K. Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum. Neuroscience. 85:1998;395-403.
65. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing the tri-nucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971-983.
66. Thibaut F., Hirsch E.C., Raisman R., Javoy-Agid F., Agid Y. Microtopography of D1 dopaminergic binding sites in the human substantia nigra: an autoradiographic study. Neuroscience. 37:1990;3873-3898.
67. Vonsattel J-P., Myers R.H., Stevens T.J., Ferrante R.J., Bird E.D., Richardson E.P. Neuropathological classification of Huntington's disease. J. Neuropath. exp. Neurol. 44:1985;559-577.
68. Yoles E., Belkin M., Schwartz M. HU-211, a nonpsychotropic cannabinoid, produces short- and long-term neuroprotection after optic nerve axotomy. J. Neurotrauma. 13:1993;49-57.